Larimar Therapeutics

Company snapshot

Larimar Therapeutics, Inc. (Nasdaq:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to des

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 5 US patent(s) indexed to this assignee profile.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Larimar Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Larimar Therapeutics.

1. Jun 5, 2026 Clinical update

   Nomlabofusp, Placebo to Nomlabofusp — Phase 3

2. May 23, 2026 Clinical update

   CTI-1601 — Phase 2

3. May 23, 2026 Clinical update

   Nomlabofusp — Phase 1

4. Aug 19, 2025 Patent grant

   Pharmaceutical composition comprising frataxin fusion protein and methods of use thereof

5. Jul 8, 2025 Patent grant

   Molecules for organelle-specific protein delivery

View all clinical trial activity →

• What is Larimar Therapeutics?

  Larimar Therapeutics is a pharma organization headquartered in Bala Cynwyd, USA. It trades on NYSE under ticker LRMR. Primary therapeutic focus areas include Friedreich Ataxia. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 5 patent record(s) to this entity fr

• Is Larimar Therapeutics publicly traded?

  Yes. Larimar Therapeutics is listed with ticker LRMR on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Larimar Therapeutics develop or market?

  We link 2 drug profile(s) where Larimar Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/larimar-therapeutics#company-drugs.

• What are the latest developments for Larimar Therapeutics?

  In the last 12 months our linked public records show 3 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does Larimar Therapeutics focus on?

  Larimar Therapeutics focuses on Friedreich Ataxia based on our analysis of their pipeline programs and drug development activities.